In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake

European Journal of Pharmacology

Volumn 484, Issue 2-3, 2004, Pages 249-257

  De Lago, Eva ^a   Ligresti, Alessia ^b   Ortar, Giorgio ^b,c   Morera, Enrico ^b,c   Cabranes, Ana ^a   Pryce, Gareth ^d   Bifulco, Maurizio ^e   Baker, David ^d   Fernandez Ruiz, Javier ^a   Di Marzo, Vincenzo ^b  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b CNR Consiglio Nazionale delle Ricerche   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF SALERNO   (Italy)

Author keywords

Anandamide; Cannabinoid; Cannabinoid receptor; Multiple sclerosis; Transporter; Uptake

Indexed keywords

AMINE; ANANDAMIDE; ANANDAMIDE REUPTAKE INHIBITOR; BLOCKING AGENT; ETHANOLAMINE DERIVATIVE; N ARACHIDONOYL(2 METHYL 4 HYDROXYPHENYL)AMINE; N OLEOYL(1' HYDROXYBENZYL) 2' ETHANOLAMINE; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG ACTIVITY; DRUG MECHANISM; DRUG RESPONSE; DRUG SYNTHESIS; LOCOMOTION; MALE; MOTOR ACTIVITY; MOUSE; MULTIPLE SCLEROSIS; NOCICEPTION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT; SPASTICITY;

EID: 1642505613     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2003.11.027     Document Type: Article

References (51)

1. Ahluwalia J., Yaqoob M., Urban L., Bevan S., Nagy I. Activation of capsaicin-sensitive primary sensory neurones induces anandamide production and release. J. Neurochem. 84:2003;585-591.
2. Baker D., Pryce G., Croxford J.L., Brown P., Pertwee R.G., Huffman J.W., Layward L. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature. 404:2000;84-87.
3. Baker D., Pryce G., Croxford J.L., Brown P., Pertwee R.G., Makriyannis A., Khanolkar A., Layward L., Fezza F., Bisogno T., Di Marzo V. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J. 15:2001;300-302.
4. Baker D., Pryce G., Giovannoni G., Thompson A.J. The therapeutic potential of Cannabis. Lancet Neurol. 5:2003;291-298.
5. Basavarajappa B.S., Saito M., Cooper T.B., Hungund B.L. Chronic ethanol inhibits the anandamide transport and increases extracellular anandamide levels in cerebellar granule neurons. Eur. J. Pharmacol. 466:2003;73-83.
6. Beltramo M., Piomelli D. Carrier-mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2-arachidonylglycerol. Neuroreport. 11:2000;1231-1235.
7. Beltramo M., Stella N., Calignano A., Lin S.Y., Makriyannis A., Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science. 277:1997;1094-1097.
8. Bisogno T., Melck D., Bobrov Myu. , Gretskaya N.M., Bezuglov V.V., De Petrocellis L., Di Marzo V. N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem. J. 351:2000;3817-3824.
9. Bisogno T., Maccarrone M., De Petrocellis L., Jarrahian A., Finazzi-Agro A., Hillard C., Di Marzo V. The uptake by cells of 2-arachidonoylglycerol, an endogenous agonist of cannabinoid receptors. Eur. J. Biochem. 268:2001;982-989.
10. Brooks J.W., Pryce G., Bisogno T., Jaggar S.I., Hankey D.J., Brown P., Bridges D., Ledent C., Bifulco M., Rice A.S., Di Marzo V., Baker D. Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB(1)/CB(2) receptors. Eur. J. Pharmacol. 439:2002;83-92.
11. Chemin J., Monteil A., Perez-Reyes E., Nargeot J., Lory P. Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide. EMBO J. 20:2001;7033-7040.
12. Cravatt B.F., Demarest K., Patricelli M.P., Bracey M.H., Giang D.K., Martin B.R., Lichtman A.H. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. U. S. A. 98:2001;9371-9376.
13. De Lago E., Fernandez-Ruiz J., Ortega-Gutierrez S., Viso A., Lopez-Rodriguez M.L., Ramos J.A. UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide. Eur. J. Pharmacol. 449:2002;99-103.
14. De Petrocellis L., Bisogno T., Davis J.B., Pertwee R.G., Di Marzo V. Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett. 483:2000;52-56.
15. De Petrocellis L., Bisogno T., Maccarrone M., Davis J.B., Finazzi-Agro A., Di Marzo V. The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J. Biol. Chem. 276:2001;12856-12863.
16. Deutsch D.G., Glaser S.T., Howell J.M., Kunz J.S., Puffenbarger R.A., Hillard C.J., Abumrad N. The cellular uptake of anandamide is coupled to its breakdown by fatty-acid amide hydrolase. J. Biol. Chem. 276:2001;6967-6973.
17. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 18:1992;1946-1949.
18. Di Marzo V., Fontana A. Anandamide, an endogenous cannabinomimetic eicosanoid: killing two birds with one stone. Prostaglandins Leukot. Essent. Fat. Acids. 53:1995;1-11.
19. Di Marzo V., Fontana A., Cadas H., Schinelli S., Cimino G., Schwartz J.C., Pomelli D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature. 372:1994;686-691.
20. Di Marzo V., Melck D., Bisogno T., De Petrocellis L. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci. 21:1998;521-528.
21. Di Marzo V., Bisogno T., De Petrocellis L., Melck D., Orlando P., Wagner J.A., Kunos G. Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Eur. J. Biochem. 264:1999;258-267.
22. Di Marzo V., Lastres-Becker I., Bisogno T., De Petrocellis L., Milone A., Davis J.B., Fernandez-Ruiz J.J. Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues. Eur. J. Pharmacol. 420:2001;123-131.
23. Di Marzo V., Griffin G., De Petrocellis L., Brandi I., Bisogno T., Williams W., Grier M.C., Kulasegram S., Mahadevan A., Razdan R.K., Martin B.R. A structure/activity relationship study on arvanil, an endocannabinoid and vanilloid hybrid. J. Pharmacol. Exp. Ther. 300:2002;984-991.
24. Dinh T.P., Carpenter D., Lesile F.M., Freund T.F., Katona I., Sensi S.L., Kathuria S., Piomelli D. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc. Natl. Acad. Sci. U. S. A. 99:2002;10819-10824.
25. Fezza F., Bisogno T., Minassi A., Appendino G., Mechoulam R., Di Marzo V. Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for its quantification in rat tissues. FEBS Lett. 513:2002;294-298.
26. Girard P., Pansart Y., Coppe M.-C., Gillardin J.-M. Nefopam reduces thermal hypersensitivity in acute and postoperative pain models in the rat. Pharmacol. Res. 44:2001;541-545.
27. Giuffrida A., Rodriguez de Fonseca F., Nava F., Loubet-Lescoulie P., Piomelli D. Elevated circulating levels of anandamide after administration of the transport inhibitor, AM404. Eur. J. Pharmacol. 408:2000;161-168.
28. Glaser S.T., Abumrad N.A., Fatade F., Kaczocha M., Studholme K.M., Deutsch D.G. Evidence against the presence of an anandamide transporter. Proc. Natl. Acad. Sci. U. S. A. 100:2003;4269-4274.
29. Gonzalez S., Romero J., de Miguel R., Lastres-Becker I., Villanua M.A., Makriyannis A., Ramos J.A., Fernandez-Ruiz J.J. Extrapyramidal and neuroendocrine effects of AM404, an inhibitor of the carrier-mediated transport of anandamide. Life Sci. 65:1999;327-336.
30. Hanus L., Abu-Lafi S., Fride E., Breuer A., Vogel Z., Shalev D.E., Kustanovich I., Mechoulam R. 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc. Natl. Acad. Sci. U. S. A. 98:2001;3662-3665.
31. Hillard C.J., Jarrahian A. The movement of N-arachidonoylethanolamine (anandamide) across cellular membranes. Chem. Phys. Lipids. 108:2000;123-134.
32. Hillard C.J., Edgemond W.S., Jarrahian A., Campbell W.B. Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion. J. Neurochem. 69:1997;631-638.
33. Huang S.M., Bisogno T., Trevisani M., Al-Hayani A., De Petrocellis L., Fezza F., Tognetto M., Petros T.J., Krey J.F., Chu C.J., Miller J.D., Davies S.N., Geppetti P., Walker J.M., Di Marzo V. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc. Natl. Acad. Sci. U. S. A. 99:2002;8400-8405.
34. Izzo A.A., Capasso F., Costagliola A., Bisogno T., Marsicano G., Ligresti A., Matias I., Capasso R., Pinto L., Borrelli F., Cecio A., Lutz B., Mascolo N., Di Marzo V. An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice. Gastroenterology. 125:2003;765-774.
35. Jarrahian A., Manna S., Edgemond W.S., Campbell W.B., Hillard C.J. Structure-activity relationships among N-arachidonylethanolamine (Anandamide) head group analogues for the anandamide transporter. J. Neurochem. 74:2000;2597-2606.
36. Kathuria S., Gaetani S., Fegley D., Valino F., Duranti A., Tontini A., Mor M., Tarzia G., La Rana G., Malignano A., Giustino A., Tattoli M., Palmery M., Cuomo V., Piomelli D. Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med. 9:2003;76-81.
37. Lastres-Becker I., de Miguel R., De Petrocellis L., Makriyannis A., Di Marzo V., Fernandez-Ruiz J. Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease. J. Neurochem. 84:2003;1097-1109.
38. Lopez-Rodriguez M.L., Viso A., Ortega-Gutierrez S., Lastres-Becker I., Gonzalez S., Fernandez-Ruiz J., Ramos J.A. Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors. J. Med. Chem. 44:2001;4505-4508.
39. Lopez-Rodriguez M.L., Viso A., Ortega-Gutierrez S., Fowler C.J., Tiger G., de Lago E., Fernandez-Ruiz J., Ramos J.A. Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: comparison with effects on fatty acid amidohydrolase. J. Med. Chem. 46:2003;1512-1522.
40. Maccarrone M., van der Stelt M., Rossi A., Veldink G.A., Vliegenthart J.F., Agro A.F. Anandamide hydrolysis by human cells in culture and brain. J. Biol. Chem. 273:1998;32332-32339.
41. Maccarrone M., Bari M., Lorenzon T., Bisogno T., Di Marzo V., Finazzi-Agro A. Anandamide uptake by human endothelial cells and its regulation by nitric oxide. J. Biol. Chem. 275:2000;13484-13492.
42. Maccarrone M., De Petrocellis L., Bari M., Fezza F., Salvati S., Di Marzo V., Finazzi-Agro A. Lipopolysaccharide downregulates fatty acid amide hydrolase expression and increases anandamide levels in human peripheral lymphocytes. Arch. Biochem. Biophys. 393:2001;321-328.
43. Maccarrone M., Gubellini P., Bari M., Picconi B., Battista N., Centone D., Bernardi G., Finazzi-Agro A., Calabresi P. Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism. J. Neurochem. 85:2003;1018-1025.
44. Martin B.R., Beletskaya I., Patrick G., Jefferson R., Winckler R., Deutsch D.G., Di Marzo V., Dasse O., Mahadevan A., Razdan R.K. Cannabinoid properties of methylfluorophosphonate analogs. J. Pharmacol. Exp. Ther. 294:2000;1209-1218.
45. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., Gopher A., Almog S., Martin B.R., Compton D.R.et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 29:1995;83-90.
46. Ortar G., Ligresti A., De Petrocellis L., Morera E., Di Marzo V. Novel selective and metabolically stable inhibitors of anandamide cellular uptake. Biochem. Pharmacol. 65:2003;1473-1481.
47. Pertwee R.G. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Ther. 74:1997;129-180.
48. Porter A.C., Sauer J.M., Knierman M.D., Becker G.W., Berna M.J., Bao J., Nomikos G.G., Carter P., Bymaster F.P., Leese A.B., Felder C.C. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J. Pharmacol. Exp. Ther. 301:2002;1020-1024.
49. Sugiura T., Kondo S., Sukagawa A., Natane S., Shinoda A., Itoh K., Yamashita A., Waku K. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 4:1995;89-97.
50. Ueda N., Yamanaka K., Katayama K., Goparaju S.K., Suzuki H., Yamamoto S. Alkaline and acid amidases hydrolyzing anandamide and other N-acylethanolamines. World Rev. Nutr. Diet. 88:2001;215-222.
51. Walker J.M., Huang S.M. Endocannabinoids in pain modulation. Prostaglandins Leukot. Essent. Fat. Acids. 66:2002;235-242.